Free Trial

Cytek Biosciences (CTKB) Stock Price, News & Analysis

$5.30
-0.14 (-2.57%)
(As of 09/6/2024 ET)
Today's Range
$5.26
$5.48
50-Day Range
$5.09
$6.73
52-Week Range
$3.80
$9.87
Volume
578,273 shs
Average Volume
684,335 shs
Market Capitalization
$695.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
60.4% Upside
$8.50 Price Target
Short Interest
Healthy
3.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.11) to $0.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

406th out of 910 stocks

Analytical Instruments Industry

14th out of 26 stocks

CTKB stock logo

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

CTKB Stock News Headlines

Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Cytek Biosciences Reports Second Quarter 2024 Financial Results
Cytek Biosciences, earnings: here's what to expect
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Cytek Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2024
Today
9/07/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+60.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-12,150,000.00
Pretax Margin
-8.22%

Debt

Sales & Book Value

Annual Sales
$197.71 million
Cash Flow
$0.02 per share
Book Value
$2.96 per share

Miscellaneous

Free Float
118,671,000
Market Cap
$695.75 million
Optionable
Optionable
Beta
1.31
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 60)
    President, CEO & Chairman of the Board
    Comp: $964.21k
  • Dr. Ming Yan Ph.D. (Age 61)
    CTO & Director
    Comp: $616.26k
  • Ms. Valerie T. Barnett J.D. (Age 48)
    Chief Legal Officer
    Comp: $535.98k
  • Mr. William D. McCombe (Age 66)
    Chief Financial Officer
  • Mr. Chris Williams (Age 55)
    Chief Operating Officer
  • Dr. Allen B. Poirson Ph.D. (Age 64)
    Senior Vice President of Business & Corporate Development
  • Dr. Philippe Busque Ph.D.
    Senior Vice President of Global Sales & Services
  • Mr. Patrik Sebastian Jeanmonod (Age 57)
    Head of Corporate Development Analytics
    Comp: $412.54k

CTKB Stock Analysis - Frequently Asked Questions

How have CTKB shares performed this year?

Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB shares have decreased by 41.9% and is now trading at $5.30.
View the best growth stocks for 2024 here
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.05. The business earned $46.62 million during the quarter, compared to analysts' expectations of $49.02 million. Cytek Biosciences had a negative net margin of 8.88% and a negative trailing twelve-month return on equity of 3.75%.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Top institutional shareholders of Cytek Biosciences include Dimensional Fund Advisors LP (1.12%), Millennium Management LLC (0.72%), Bank of New York Mellon Corp (0.61%) and Principal Financial Group Inc. (0.37%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, Jack Ball and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners